Innovation in
Antibody
Development.

Vybion is a leading developer of human monoclonal antibody drugs for unmet needs with large markets. Our proprietary technologies bring improved economy and decrease time to market.

LATEST NEWS:
December 3, 2009
Vybion receives grant award from NIH for “Rapid Isolation of High Affinity Human Antibodies from Large Synthetic Libraries”. More»
November 1, 2009
Lee Henderson, Ph.D. was invited to give a presentation at the PepCon Conference in Beijing, China in late March. More»
July 2009
Vybion file patent for novel pegylation technology to improve and fine tune the pharmacokinetic properties of biologics. More»
Jun 10, 2009
Ithaca, NY: Vybion has received a $1.3M subcontract on at $7.1M NIH Cooperative Agreement to develop diagnostics for Lassa Virus, a deadly hemorrhagic virus endemic in West Africa. More»
Oct 1, 2008
Ithaca, NY: Vybion announces the addition of Drs. Matthew DeLisa, William Ball and Andrew Norman to its Scientific Advisory Board. More»
Jul 10, 2008
Denver, CO: Corgenix Medical Corporation expands effort for developing test kits for viral hemorrhagic fever detection. More»
Click for more Vybion news...»

  • Human monoclonal antibody selection
  • Affinity maturation simultaneously with selection
  • Protein solubility optimization
  • Molecule format engineering
  • Complete development and process package